Related Experiment Video
Updated: Jun 19, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Emerging treatments for viral myocarditis
1Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. amat@kuhp.kyoto-u.ac.jp
Hepatitis C virus is an emerging cause of viral myocarditis. Promising new treatments include specific immunosuppressors, immunomodulation, and stem cell therapy, while traditional treatments are ineffective.
Area of Science:
- Cardiology
- Virology
- Immunology
Background:
- Viral myocarditis is typically caused by enterovirus and adenovirus.
- Hepatitis C virus is increasingly recognized as a cause of viral myocarditis.
Purpose of the Study:
- To review current and emerging therapies for viral myocarditis.
- To highlight novel approaches beyond traditional treatments.
Main Methods:
- Review of existing literature on viral myocarditis treatments.
- Analysis of preclinical and clinical trial data for antiviral and immunomodulatory agents.
Main Results:
- Interferon-based antiviral therapies are in clinical trials.
- Novel therapies like vaccines and virus receptors are in preclinical development.
- Specific immunosuppressors (e.g., FTY720) and immunomodulation (e.g., interleukin-10) show promise.
Conclusions:
- Traditional immunosuppressants are ineffective for viral myocarditis.
- Targeting inflammatory pathways (NF-kappaB, angiotensin II, endothelin) is effective.
- Embryonic stem cell therapy warrants further investigation for viral myocarditis treatment.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Myocarditis I: Introduction
Endocarditis III: Medical Management
Pericarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests